Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Samtheo Biopharma has entered into a license agreement, through its subsidiary, Lyndor Biosciences, with Moffitt Cancer Center, gaining exclusive worldwide rights to a small molecule that selectively inhibits the activation of all three isoforms of Akt.
Subscribe to our email newsletter
Persistent activation of the Akt pathway has been found to play an important role in oncogenesis and chemo- and radiation-resistance and to be responsible for cancer cell proliferation, survival and invasiveness.
Through this license, Lyndor plans to develop and commercialize the new anticancer agent, which it refers to as LD-101, for refractory and resistant tumors as well as metastatic malignancies.
Under the license agreement, Lyndor has agreed to pay Moffitt when various milestones are reached and provide Moffitt with running royalties on the sales of licensed products.
Susan Rosenbaum, chairman and CEO of Samtheo, said: “Given time, most cancers will relapse, become resistant and, ultimately, refractory. In fact, most become metastatic before detection. Lyndor’s agreement with Moffitt will enable Lyndor to develop this targeted therapeutic for personalized medicine in the treatment of patients with these difficult-to-treat diseases.”